Key Takeaways
- Steady quarter, India shines: Revenue of Rs. 1,001 crore grew 13% YoY, driven by a 22% surge in the domestic formulation business. International growth was muted at 3% due to a CDMO deferral, but management expects a sharp H2 recovery.
- Domestic franchise is the engine: India business grew 11% vs. the IPM's 7.6%, powered by chronic therapies. Cardiology rank jumped from 15 to 8 in three years, and the Sporlac probiotic franchise hit a Rs. 137 crore MAT with a 29% CAGR.
- CDMO stumble is a timing issue, not a demand one: A $2 million order slipped to Q3 due to a raw material delay. The order book for H2 is robust, and the medium-term ambition to double the business to $100 million remains firmly in place.
- Margins held firm despite integration drag: Operating EBITDA margin was 28.4%. Excluding the dilutive Ophthalmology acquisition, gross margin improved over 150 bps YoY, while gross debt was slashed from Rs. 358 crore to Rs. 82 crore.
- What to watch next quarter: The pace of the CDMO recovery in Q3, the sustainability of the 22% domestic growth as the Ophthalmology base normalizes, and any update on the 20 international product filings planned through FY27.
Domestic Business: The Growth Engine
- Broad-based outperformance: The 22% headline growth (12% organic, excluding Ophthalmology) was fueled by market share gains in chronic therapies, with the company growing at 11% versus the IPM's 7.6% as per IQVIA MAT data.
- Cardiology is the star: The franchise has driven a rank improvement from 15 to 8 in three years. The Razel franchise grew 28% YoY, outpacing a market growing at 20%, driven by a focused strategy that prioritizes it within the chronic sales team and expands the prescriber base among cardiologists and consulting physicians.
- Azmarda's post-LOE trajectory: The brand has reached a Rs. 67 crore MAT and is projected to grow at a 15-20% CAGR for the next five years, with management expecting a sequential gain of 5,000-7,000 units per quarter to reach 140,000-145,000 units by FY25-end.
- Probiotic powerhouse: The Sporlac franchise has scaled from Rs. 83 crore to Rs. 137 crore in two years, a 29% CAGR, through lifecycle management and better distribution. New launches like Sporlac GG for pediatrics continue to expand the franchise.
- Ophthalmology integration on track: The acquired portfolio's quarterly run-rate has increased from Rs. 40 crore to Rs. 48 crore, supported by a prescriber base expansion from 7,000 to 13,500 ophthalmologists and a field force increase from 65 to 105. The target is Rs. 185-190 crore for the portfolio.
- Volume-led growth strategy: The company aims to maintain an incremental 3-4% delta over IPM volume growth, with Cilacar franchise volumes growing at 12-14% through a segmentation strategy targeting different hypertensive patient profiles with specific SKUs.
Chopra: "If you look at in a country like India, 10 crore plus people suffer from hypertension and one in four patients is undiagnosed. So, we have basically put the entire positioning of segmentation, targeting and positioning for all our different SKUs to different specialty for different indication."
CDMO Business: A Hiccup, Not a Reset
- The Q2 miss: The international business grew only 3% YoY because a couple of million dollars in CDMO revenue was deferred to Q3. The cause was a delay in specific excipients from regulated markets, not a vendor change or demand issue.
- H2 recovery is de-risked: Management has guided for "very high double-digit growth" of 20%+ in H2, backed by a robust order book for Q3 and Q4. The full-year assumption is for the CDMO business to close flattish over FY24.
- The $100 million ambition is intact: The medium-to-long-term target to double the business from ~$50 million to $100 million in 3-5 years stands. Growth will come from new drug delivery systems, new geographies like Brazil and Europe, and new categories like lozenges.
- Capacity expansion underway: The company has bought a 200-crore lozenges capacity and is expanding injectable IV capacity from 54 lakh to 75-78 lakh units per month. Investments are also being made in a throat spray line for a principal CDMO partner.
Khanna: "No, this is not related to any change in vendor, nothing of concern, just specific excipients got delayed... Overall, we see very strong traction for our CDMO business in H2."
International Business: A Transition Year
- Mixed geography performance: While South Africa and the US recorded double-digit growth, and Russia and ROW branded generics had high single-digit performance, the overall 3% growth was dragged down by the CDMO deferral and the tail-end of a South Africa tender rationalization that had taken a Rs. 150 crore haircut over five quarters.
- South Africa reset complete: The tender business rationalization is now in the base, and the business is expected to grow at a normalized 10-12% going forward.
- ROW generics: FY27 inflection expected: The branded generic business is expected to see better traction from new launches by FY27, with a target of approximately Rs. 100 crore per quarter.
- Regulatory filings as a growth lead indicator: The company plans 20 product filings across international markets. The first phase of 10 products should receive regulatory approvals by September/October calendar year 2025 (Q3/Q4 FY26), with the second set of 10 products providing incremental gains in FY27. In the US, the cadence is close to 3 filings a year with approvals expected in the next 9-12 months.
Margins & Capital Allocation
- Margin resilience: Operating EBITDA margin was 28.4%. Excluding the Ophthalmology portfolio, which carries a limited margin, gross margin improved by more than 150 bps YoY due to cost optimization, a favorable product mix, and price growth.
- Guidance maintained: The company reiterated its margin outlook of 26-28%, with an endeavor to be in the higher range, despite anticipating a marginal Q4 dip in the India business due to inventory normalization.
- Debt nearly gone: Gross debt was reduced from Rs. 358 crore in March 2024 to just Rs. 82 crore by September 2024. Finance costs consequently fell from Rs. 10 crore to Rs. 2 crore YoY.
- Cash flow and capex: H1 operating cash flow was Rs. 380 crore, slightly lower than Rs. 421 crore last year due to a Rs. 34 crore increase in cash tax and inventory build-up for anticipated EPA costs and the Ophthalmology integration. H2 capex is planned at Rs. 50-55 crore, taking the full year to over Rs. 100 crore, with an annual run-rate of Rs. 100-120 crore expected going forward.
- ESOP cost visibility: An additional Rs. 25-30 crore in ESOP costs is expected in H2, with an annual run-rate of around Rs. 45 crore.
Levers for Future Growth
- Lifecycle management as a moat: The strategy of extending large brands through new formulations is critical. Recent examples include Metrogyl ER, Rantac OD, Sporlac GG, and a new Metrogyl DG LA Gel for dental health.
- New launch cadence: The company is launching a new Ophthalmology product every three months, with a probiotic for dental health expected in December. A syrup formulation of the iron supplement Bisfer XT is also in the pipeline.
- MR productivity over expansion: With no plans to add medical representatives in the next 12-18 months, the focus is on improving productivity to 10-12% and climbing the prescription rankings from 16th to the top 10.
- CDMO category expansion: Beyond lozenges, the company is entering immunity and wellness products for the pan-European market next year and pain lozenges for Brazil by the end of next year.
Chopra: "If you ask aspiration, we want to inch up in terms of where we want to be in terms of prescription, we want to be in top 10 by the way in terms of prescription."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Domestic business growth | 12%-14% growth in H2 FY25; continue to outgrow market | H2 FY25 |
| CDMO business recovery | "Very high double digit growth rate to 20% plus" in H2; full year flattish over FY24 | H2 FY25 / FY25 |
| Azmarda volume trajectory | Reach 140,000-145,000 units; mid-teens growth thereafter | FY25-end / beyond |
| Ophthalmology portfolio target | Achieve Rs. 185-190 crore; expand prescriber base to 16,000-17,000 | Next 12 months |
| International regulatory approvals | First set of 10 product approvals expected | Sep/Oct CY25 (Q3/Q4 FY26) |
| CDMO revenue ambition | Double business from ~$50 million to $100 million | 3-5 years |
| Operating EBITDA margin | Maintain 26%-28% range; endeavor to be at higher end | Ongoing |
| Capex run-rate | Annual capex of Rs. 100-120 crore with 15-20% for growth | Ongoing |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Revenue | ₹1,001 cr, +13% YoY |
| Domestic revenue | ₹588 cr, +22% YoY; 59% of H1 turnover |
| Domestic revenue excl. Ophthalmology | +12.6% YoY |
| International revenue | ₹413 cr, +3% YoY |
| Gross margin | 66.2%, excl. Ophthalmology improved >150 bps YoY |
| Operating EBITDA (excl. ESOP) | ₹285 cr, +13% YoY; margin 28.4% |
| Net profit | ₹175 cr, +16% YoY |
| Operating EBITDA margin guidance | 26%–28%, maintained; endeavor to be at higher range |
| Domestic volume growth (excl. Ophthal) | ~5% vs IPM <1.5% |
| Domestic price growth (excl. Ophthal) | ~6% |
| IQVIA growth vs IPM (MAT Sep 24) | 11% vs IPM 7.6% |
| CDMO revenue deferred | US $2 mn deferred to Q3 FY25 due to material availability |
| CDMO H2 FY25 growth expectation | Very high double digit, 20%+ |
| CDMO medium-term aspiration | $100 mn in 3–5 years, maintained |
| Azmarda monthly run rate | 125,000 units, ~₹6 cr monthly value; targeting 140,000–145,000 units by FY25-end |
| Razel franchisee growth (IQVIA MAT Sep 24) | +28% YoY |
| Sporlac franchisee revenue (IQVIA MAT Sep 24) | ₹137 cr, 29% CAGR from ₹83 cr in MAT Sep 22 |
| Cilacar and Cilacar-T volume growth (past 3 years) | 12%–14% |
| Ophthalmology portfolio quarterly run rate | ~₹48 cr, acquired at ~₹40 cr steady-state; targeting ₹185–₹190 cr |
| Ophthalmology prescriber coverage | ~13,500 ophthalmologists, expanding to 16,000–17,000 in 12 months |
| MR base | 2,300 including Ophthalmology; no additions planned in 12–18 months |
| MR productivity | ~₹11 lakh annually |
| Gross debt (30 Sep 2024) | ₹82 cr vs ₹358 cr on 31 Mar 2024 |
| Finance costs | ₹2 cr vs ₹10 cr in Q2 FY24 |
| MTM FOREX impact | ₹4 cr loss, primarily Ruble depreciation |
| Operating cash flow (H1 FY25) | ₹380 cr vs ₹421 cr in H1 FY24 |
| Net CAPEX (H1 FY25) | ₹53 cr vs ₹93 cr in H1 FY24; full-year guidance ₹100+ cr |
| ESOP cost (Q2 FY25) | ₹14 cr; full-year expectation ~₹45 cr |
| India business H2 FY25 growth expectation | 12%–14% |
| International business FY25 growth expectation | High single digit for full year, double digit in H2 |